Core Viewpoint - Moderna's experimental flu vaccine has successfully met the primary endpoint in its Phase 3 clinical trial, leading to a pre-market stock increase of over 6% [1]. Stock Performance - Moderna's stock price rose by 6.22% in pre-market trading, reaching $28.650 [1]. - The stock's previous closing price was $27.540, indicating a significant upward movement [1]. - The stock's trading volume in pre-market was approximately 28,900 shares, with a total market capitalization of $10.504 billion [1]. Financial Metrics - The stock has a price-to-earnings (P/E) ratio of loss, reflecting its current financial performance [1]. - The stock's 52-week high was $129.390, while the 52-week low was $23.150, showing substantial volatility [1]. - The average price in pre-market trading was $28.428, with a trading range of $27.680 to $29.180 [1].